# Emerald Health signs Lonza to manufacture cannabinoid API

Emerald Health Pharmaceuticals signed a contract with Lonza to manufacture its synthetic cannabinoid derivative VCE-004.8, including API in Nansha, China, hard capsules in Edinburgh, Scotland, and soft gels in Ploermel, France.

- Type: Contract
- Announced: 2019-02-17
- Where: Nansha, China; Edinburgh, Scotland; Ploermel, France, China
- Status: announced
- Products: cannabinoid API VCE-004.8, liquid-filled hard and soft-gel capsules
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Lonza Group AG](https://endata.com/companies/20735.md) (supplier)
- [Emerald Health Pharmaceuticals](https://endata.com/companies/37381.md) (customer)

## Sources

- [doi.org](https://doi.org/10.1021/cen-09707-buscon12), 2019-02-17: "Emerald Health Pharmaceuticals has signed Lonza to make a synthetic derivative of cannabidiol it is developing to treat multiple sclerosis and systemic scleroderma."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.